Cargando…

Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer

Breast cancer (BC) is the most common malignancy among women in Canada. Adjuvant treatment in early BC can reduce the risk of BC recurrence. Historically, the decision for adjuvant chemotherapy for early BC was made only based on clinical and tumour characteristics. In recent years, there has been a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pauls, Mehrnoosh, Chia, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325032/ https://www.ncbi.nlm.nih.gov/pubmed/35877267 http://dx.doi.org/10.3390/curroncol29070407

Ejemplares similares

Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
por: Pauls, Mehrnoosh, et al.
Publicado: (2022)

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

Genomic Assays in Node Positive Breast Cancer Patients: A Review
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
por: Barbi, Mali, et al.
Publicado: (2021)

Corrigendum: Genomic Assays in Node Positive Breast Cancer Patients: A Review
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Gene Expression Assays for Early-Stage Hormone Receptor–Positive Breast Cancer: Understanding the Differences
por: Nunes, Ana Tablante, et al.
Publicado: (2017)

Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
por: Gollamudi, Jahnavi, et al.
Publicado: (2016)

The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer
por: Chen, Keyu, et al.
Publicado: (2022)

Clinical relevance of the 21-gene Recurrence Score(®) assay in treatment decisions for patients with node-positive breast cancer in the genomic era
por: Mamounas, Eleftherios P., et al.
Publicado: (2018)

Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan
por: Yamauchi, Hideko, et al.
Publicado: (2014)

Best Practices for Genomic Assay Testing in Early-Stage Breast Cancer: Clinical and Medicolegal Perspectives
por: Seidman, Andrew D., et al.
Publicado: (2017)

The Role of the 21-Gene Recurrence Score(®) Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
por: Yordanova, Mariya, et al.
Publicado: (2022)

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
por: Blanchette, Phillip, et al.
Publicado: (2022)

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
por: Stemmer, Salomon M., et al.
Publicado: (2013)

Incorporation of the number of positive lymph nodes leads to better prognostic discrimination of node-positive early stage cervical cancer
por: Zhou, Juan, et al.
Publicado: (2017)

Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018)

Axillary management in early breast cancer with onset surgical management and positive sentinel lymph node
por: Vasquez, Lia Pamela Rebaza, et al.
Publicado: (2021)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
por: Hajjar, Ali, et al.
Publicado: (2019)

Survival analysis and nomogram for early-stage occult breast cancer with positive lymph nodes based on the SEER database
por: Man, Xiaochu, et al.
Publicado: (2022)

The prognostic value of the number of positive lymph nodes and the lymph node ratio in early‐stage cervical cancer
por: Olthof, Ester P., et al.
Publicado: (2022)

The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression
por: Wang, Yubo, et al.
Publicado: (2022)

Clinical validity and clinical utility of Ki67 in early breast cancer
por: Kreipe, Hans, et al.
Publicado: (2022)

Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
por: Miles, Jennifer, et al.
Publicado: (2018)

Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor–Positive Breast Cancer
por: Carleton, Neil, et al.
Publicado: (2021)

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
por: Hannouf, Malek B, et al.
Publicado: (2012)

Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
por: Prakash, Ipshita, et al.
Publicado: (2022)

Targeting and limiting surgery for patients with node-positive breast cancer
por: Caudle, Abigail S., et al.
Publicado: (2015)

Dosimetric evaluation and systematic review of radiation therapy techniques for early stage node-negative breast cancer treatment
por: Chan, Tabitha Y, et al.
Publicado: (2018)

The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer
por: Kay, Charlene, et al.
Publicado: (2023)

Prediction of lymph node metastasis and sentinel node navigation surgery for patients with early-stage gastric cancer
por: Shida, Atsuo, et al.
Publicado: (2016)

Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report
por: Schuster, Steven R., et al.
Publicado: (2012)

Staging for Breast Cancer With Internal Mammary Lymph Nodes Metastasis: Utility of Incorporating Biologic Factors
por: Lian, Chen-Lu, et al.
Publicado: (2021)

The management concept of breast cancer with clinically node-negative/imaging node-positive disease
por: Bi, Zhao, et al.
Publicado: (2023)

Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion
por: Mahdi, Haider, et al.
Publicado: (2015)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
por: Pop, Lucian, et al.
Publicado: (2019)

Identification and Biopsy of Sentinel Lymph Node in Early-Stage Cervical Carcinoma: Diagnostic Accuracy and Clinical Utility
por: Koutroumpa, Ioanna, et al.
Publicado: (2022)

Advanced diagnostic imaging of sentinel lymph node in early stage breast cancer
por: Li, Ping, et al.
Publicado: (2022)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
por: Eiermann, W., et al.
Publicado: (2013)

Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
por: Criscitiello, Carmen, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_tnbifai1qpt1nr0elhor3h0oar